Michael Birrer, MD, PhD, on treatments targeting either VEGF or ANG2 in gynecologic cancers.
Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, on treatments targeting either VEGF or ANG2 in gynecologic cancers.
Birrer says VEGF stimulates tumor vessel growth, while ANG2 stabilizes the vessels, making both an attractive target for oncologists. Birrer adds that to date, ANG2-targeted therapies have not been as successful in trials as VEGF-targeted therapies. ANG2-targeted therapies have given patients a better progression-free survival, but the treatment has not affected patients’ overall survival rates, he says.